|
Prospective Feasibility and Phase 1/2 Trial of Preoperative Proton Beam Therapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer
|
May 18, 2023
|
PC3I Authors Charu Aggarwal |
International Journal of Radiation Oncology, Biology, Physics
|
|
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer
|
June 4, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Ronac Mamtani |
JAMA Oncology
|
|
Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
|
July 6, 2023
|
PC3I Authors Charu Aggarwal |
Advances in Radiation Oncology
|
|
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
|
July 10, 2023
|
PC3I Authors Charu Aggarwal |
Nature Medicine
|
|
MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Response
|
July 14, 2023
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens
|
July 14, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond
|
July 19, 2023
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
Zipalertinib in EGFR Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting
|
July 24, 2023
|
PC3I Authors Charu Aggarwal |
Journal of Clinical Oncology
|
|
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer
|
July 27, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Dylan G. Scholes; Peter Gabriel; Larry Shulman; Justin Bekelman |
JCO Precision Oncology
|
|
Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation
|
August 24, 2023
|
PC3I Authors Michelle Iocolano; Charu Aggarwal |
International Journal of Radiation Oncology, Biology, Physics
|
|
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
|
August 31, 2023
|
PC3I Authors Michelle Iocolano; Catherine Lai; Charu Aggarwal; Melina Marmarelis |
International Journal of Radiation Oncology, Biology, Physics
|
|
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
|
October 3, 2023
|
PC3I Authors Charu Aggarwal; Dylan G. Scholes |
British Journal of Cancer
|
|
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
|
October 9, 2023
|
PC3I Authors Michelle Iocolano; Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella |
Clinical Lung Cancer
|
|
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors
|
October 22, 2023
|
PC3I Authors Michelle Iocolano; Charu Aggarwal; Melina Marmarelis |
International Journal of Radiation Oncology, Biology, Physics
|
|
The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC
|
November 26, 2023
|
PC3I Authors Michelle Iocolano; Charu Aggarwal |
Radiotherapy and Oncology
|
|
Concurrent Circulating Tumor DNA and Tissue Genotyping-Ready for Prime Time?
|
January 22, 2024
|
PC3I Authors Charu Aggarwal |
JAMA Network Open
|
|
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era
|
January 31, 2024
|
PC3I Authors Michelle Iocolano; Charu Aggarwal |
Cancer
|
|
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels
|
March 3, 2024
|
PC3I Authors Charu Aggarwal |
Lung Cancer (Amsterdam, Netherlands)
|
